Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Semaglutide
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effectiveness of Microdosed GLP-1 on Health, Quality of Life & Longevity
Details : Semaglutide is a Peptide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Inflammation.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
July 30, 2025
Lead Product(s) : Semaglutide
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metformin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Alternative Therapies to Maintain Weight Loss After GLP-1 Therapy
Details : Metformin is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Aging.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 30, 2025
Lead Product(s) : Metformin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Semaglutide
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AgelessRx Expands to Oral GLP-1 Drops for Metabolic Health & Longevity
Details : Company offers oral sublingual drops for GLP-1 receptor agonists semaglutide, an alternate to injectables for the treatment of Type 2 diabetes, and liver disease etc.
Product Name : Oral Semaglutide Drops
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
February 05, 2025
Lead Product(s) : Semaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sirolimus
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AgelessRx’s PEARL Trial Links Rapamycin Use to Healthspan Improvement
Details : Sirolimus (rapamycin) is an mTOR inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of aging.
Product Name : Sirolimus
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 10, 2024
Lead Product(s) : Sirolimus
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Canagliflozin
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
The Efficacy and Tolerability of Canagliflozin in Healthy Individual
Details : Invokana is a HPAPI drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : HPAPI
Upfront Cash : Inapplicable
March 08, 2024
Lead Product(s) : Canagliflozin
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Acarbose
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
The Efficacy and Tolerability of Acarbose in Healthy Individuals
Details : Acarbose is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
September 16, 2022
Lead Product(s) : Acarbose
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Metformin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19
Details : Metformin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 27, 2020
Lead Product(s) : Metformin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naltrexone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome
Details : Naltrexone is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 27, 2020
Lead Product(s) : Naltrexone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sirolimus
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : University of California, Los Angeles
Deal Size : Inapplicable
Deal Type : Inapplicable
Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study
Details : Rapamycin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Aging.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 28, 2020
Lead Product(s) : Sirolimus
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : University of California, Los Angeles
Deal Size : Inapplicable
Deal Type : Inapplicable